Informatics-Driven Drug Discovery Platform

An integrated, informatics-driven drug discovery platform, based on proprietary advances in chemogenomics and bioinformatics, is designed to improve and accelerate drug candidate approval.

The platform provides an integrated view of both the target and compound components of drug attrition that allows rapid validation of targets and therapeutic approaches. Included is a comprehensive database of drug-target-indications for all prior, safe medicines mapped to the human and model organism genomes. Detailed binding site mapping, analysis, and comparison and precomputed pharmacophores are applied. These are further linked to chemical synthesis and bioassay protocols.

Called PharmaCarta, the platform was launched by Inpharmatica Ltd. (London, UK; www.inpharmatica.co.uk), which will use the platform for in-house discovery programs and also offer it for use in collaborative programs with clients. The company also recently launched Biotech Biopendium, a proteome annotation resource for high throughput annotation for target prioritization, target mining, and microarray analysis.

"The launch of Biotech Biopendium opens up a new and exciting target audience for Inpharmatica, a strategy which we are confident will create even greater opportunities for both us and our customers going forward,” said Richard Lingard, director of business development at Inpharmatica.





Related Links:
Inpharmatica